AMRI Promotes Richard A. Saffee to Vice President and General Manager of Large Scale Manufacturing

AMRI Promotes Richard A. Saffee to Vice President and General Manager of Large
                             Scale Manufacturing

PR Newswire

ALBANY, N.Y., Jan. 8, 2013

ALBANY, N.Y., Jan. 8, 2013 /PRNewswire/ --AMRI (NASDAQ: AMRI) announced today
that Richard A. Saffee has been promoted to the newly created role of Vice
President and General Manager of Large Scale Manufacturing, effective
immediately. He will continue to report to Steven R. Hagen, Ph.D., Senior Vice
President of Pharmaceutical Development and Manufacturing.

Mr. Saffee will assume oversight for large scale manufacturing in Aurangabad,
India in addition to his current responsibilities for leadership of AMRI's
large scale manufacturing and GMP business in the United States in the Capital
Region of New York. Additionally, Mr. Saffee will work with AMRI's Holywell,
UK site to assist them in their large scale manufacturing business. Mr. Saffee
will be positioned to drive synergies between the locations that will improve
quality, efficiency and delivery of world class API's. 

"We are pleased to announce this promotion of Mr. Saffee," said Dr. Hagen.
"Mr. Saffee joined AMRI in 2009 with more than 23 years of industrial and
leadership experience in the chemical manufacturing of bulk Active
Pharmaceutical Ingredients (API) for both human and animal health. Since
joining AMRI, Rick's leadership has been instrumental in many successes
achieved at the Rensselaer large scale manufacturing location. We look
forward to his leadership in our continued efforts to achieve closer
integration among all of our manufacturing facilities."

Backed by an excellent compliance history and track record, AMRI's worldwide
manufacturing facilities are equipped for Phase I through commercial API
manufacturing. As a part of AMRI's SMARTSOURCING™ initiative, this closer
integration of facilities under Mr. Saffee provides an added advantage as
customers move their compounds from early development to high potency and
large scale manufacturing. These global sites in the United States, Europe and
Asia also provide tailored solutions for the biotech and pharma industry, and
enable the efficient, cost-effective transfer of products and projects. AMRI
also provides raw materials and starting materials for cGMP manufacturing of

Before coming to AMRI, Mr. Saffee led manufacturing activities for multiple
U.S.-based operations for Pfizer Global Manufacturing. and Pfizer Global Human
Health. Prior to the acquisition of Parke-Davis by Pfizer, Mr. Saffee held
roles of increasing responsibility at Parke-Davis including Director of
Chemical Manufacturing and Area Production Manager. He has extensive knowledge
in the areas of chemical manufacturing, technology transfer, regulatory
compliance and quality standards, purchasing and materials management and
managing global relationships. He is also trained in Lean Six Sigma

Mr. Saffee earned a Master's degree in Business Administration from Grand
Valley State University in Allendale, Michigan and a Bachelor's of Science
degree in Chemical Engineering from the University of Michigan in Ann Arbor,

About AMRI
Albany Molecular Research, Inc. (AMRI) is a global contract research and
manufacturing organization offering customers fully integrated drug discovery,
development and manufacturing services. For over 21 years, AMRI has
demonstrated its adaptability as the pharmaceutical and biotechnology
industries have undergone tremendous change in response to multiple
challenges. This experience, a track record of success and locations in the
United States, Europe and Asia now provides our customers with SMARTSOURCING™,
a full range of value-added opportunities providing customers informed
decision-making, enhanced efficiency and more successful outcomes at all
stages of the pipeline. AMRI has also successfully partnered R&D programs and
is actively seeking to out-license its remaining programs for further
development. For more information about AMRI, please visit our website at or follow us on Twitter (@amriglobal).

About AMRI Rensselaer
AMRI's 23-acre Rensselaer site is located in New York State and provides
contract cGMP manufacturing of bulk active pharmaceuticals and advanced
intermediates for clinical phase scale-up requirements up to and including
full scale commercial manufacturing. The facility, which hosts over 35
customer audits each year, maintains an excellent U.S. Federal Drug
Administration (FDA) quality inspection record and is fully licensed by the
U.S. Drug Enforcement Administration (DEA) to produce Schedule I, II, III, IV
and V controlled substances. The site, which received its SafeBridge Potent
Compound Safety Certification in 2010, has a state-of-art high-potency
compound production facility that can handle quantities from grams to 120 kgs.
Combining a scientifically strong staff with our highly experienced workforce
allows the Rensselaer site to deliver its best to our customers. Currently, 26
Commercial Products are routinely manufactured from 25 kg individual batches
to 7 metric ton annual campaigns.

About AMRI India Operations
In India, AMRI offers cost-competitive chemical synthesis and kilo lab work,
as well as a reliable, large-scale manufacturing source for starting materials
and intermediates. AMRI established its presence in India in 2007. Since that
time, capabilities have been built in the areas of chemical synthesis and
manufacturing, keeping AMRI's core values of Safety, Quality and Customer
Satisfaction and Service at the forefront of the Company's business
objectives. Today, AMRI in India has significant capabilities and capacity
across the Custom Research and Manufacturing Services (CRAMS) space. AMRI's
Global Project Management Team has access to the extensive experience and
capabilities of all of the Company's global locations, and can tap into the
collective problem solving and brainpower of industry experienced managers as
needed. Numerous projects are in progress or have been completed using this
integrated model, and AMRI's operations in Hyderabad and Aurangabad, India,
are especially well-suited to be a centerpiece of a global project team.

AMRI UK provides development and manufacturing services, including
pre-clinical and Phase I – III product development, as well as commercial
manufacturing for approved products. The 14-acre site is located about 60
miles outside of Manchester, England and contains Kilo lab, pilot plant and
large-scale manufacturing capabilities. In 2012, the site received a Good
Manufacturing Practice (GMP) certificate from the Medicines and Healthcare
Regulatory Agency (MHRA) of the UK government for AMRI's manufacturing
facility in Holywell, Wales, UK, underscoring the quality of the facility and
its growth potential.


Contact: Investors - Michael Nolan, AMRI Chief Financial Officer,
+1-518-512-2261; or Media - Gina Monari, AMRI Communications, +1-518-512-2512
Press spacebar to pause and continue. Press esc to stop.